Ultragenyx Pharmaceutical Inc. (RARE) Stock
Fundamentals
Recent news

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
RARE

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
RARE

Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
RARE

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
RARE
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.35 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
RARE

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
RARE

Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
RARE

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
RARE

S&P 500, Nasdaq, Dow Set For Mixed Open? US Stock Futures Seek Direction After Fed's First Rate Hike In Three Years
S&P 500, Nasdaq, Dow Set For Mixed Open? US Stock Futures Seek Direction After Fed's First Rate Hike In Three Years
RARE

RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy
RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy
RARE

How This Gene Therapy Name Partially Reversed Its Catastrophic 44% Dive
How This Gene Therapy Name Partially Reversed Its Catastrophic 44% Dive
RARE

US FDA approves Ultragenyx's gene therapy for rare disorder
US FDA approves Ultragenyx's gene therapy for rare disorder
RARE

RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares
RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares
RARE

Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
RARE
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 1960 |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | 1979 |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 1978 |
| Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer | 1970 |
| Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP | 1973 |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | 1971 |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | 1965 |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 1965 |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations | — |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 1966 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
19 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.7 | -4.4 | -12.5 | +10.4 | ||||||||
| 2022 | -17.1 | -6.6 | +7.8 | -8.6 | -35.1 | +29.3 | -15.0 | -5.8 | -14.6 | -3.5 | -13.4 | +22.5 |
| 2023 | -0.4 | -1.7 | -12.2 | +7.9 | +12.1 | -7.0 | -7.6 | -14.3 | -5.6 | +1.7 | +7.8 | +19.1 |
| 2024 | -8.4 | +17.3 | -13.0 | -9.4 | -7.3 | -0.1 | +9.5 | +28.6 | -0.3 | -9.8 | -6.6 | -11.6 |
| 2025 | +4.6 | -1.2 | -12.2 | +15.2 | -12.7 | +0.6 | -24.7 | +5.3 | -6.1 | +15.4 | +3.8 | -31.1 |
| 2026 | +2.0 | -5.5 | -9.0 | +15.3 | -3.4 | +46.1 | -23.1 | +0.8 | -43.8 |



